A recent study demonstrates that annual blood-based multicancer early detection screening could significantly reduce late-stage cancer diagnoses and cancer mortality. Modelling different tumor growth scenarios, researchers found that annual screening provided more overall benefit than biennial screening. Although biennial screening demonstrated advantages, the findings suggest that annual screening could offer the strongest mortality reduction benefits.

Source: BMJ Open